CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 49 enrolled
Drug / intervention
Enhanced Usual Care (EOC) +1 morebehavioral
Likely dose
REVITALIZE ACT intervention: six 60-75 minute telehealth sessions approximately once a week for 6-8 weeksAI-extracted
Key inclusion· 6
  • Women ≥18 years of age
  • Diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
  • Receiving PARP inhibitors for ≥2 months
  • ECOG performance status 0-2
Key exclusion· 6
  • Untreated clinical conditions or comorbidities (e.g., anemia, hypothyroidism) that could explain fatigue
  • Chronic severe fatigue predating PARP inhibitor use
  • Pregnant women
  • Prisoners

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04525183
NCT04525183N/ACompleted

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

Dana-Farber Cancer Institute·interventional·Posted Aug 25, 2020·Updated Nov 15, 2024

In Brief

A clinical study evaluating Enhanced Usual Care (EOC) and REVITALIZE ACT Intervention for Ovarian Cancer and 3 related conditions. Completed, enrolled 49 participants across 2 sites.

Detailed Summary

This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 25, 2020
Enrollment StartDec 2, 2020
Primary CompletionAug 9, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.9 years ago

Interventions

Enhanced Usual Care (EOC)behavioral

Educational materials

REVITALIZE ACT Interventionbehavioral

Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks